For Investors

Corporate Profile
AVEO Oncology is a biopharmaceutical company committed to discovering and developing targeted therapies designed to provide substantial impact in the lives of people with cancer by addressing unmet medical needs. AVEO’s proprietary Human Response Platform provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates.
Stock Quote
AVEO (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Price$0.95
Change (%) Stock is Up 0.03 (4.40%)
Volume221,550
Data as of 01/30/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press Releases 
DateTitle 
01/12/15AVEO to Present at the 33rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 12, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael P. Bailey, president and chief executive officer, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015 at 12:00PM (PT) in San Francisco. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at aveooncology.com. A replay of the webca... 
Printer Friendly Version
01/09/15AVEO Names Michael N. Needle, M.D., As Chief Medical Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced the appointment of Michael N. Needle, M.D., to the position of Chief Medical Officer. In this role, Dr. Needle, a board certified hematologist/oncologist, will take a leadership role in evaluating clinical development strategies for advancement of the Company’s partnered and proprietary pipeline programs. He will report to Michael Bailey, AVEO’s president and ch... 
Printer Friendly Version
01/08/15AVEO Receives Confirmation of Eligibility for Submission of a Tivozanib Marketing Authorization Application to the European Medicines Agency
Company to Evaluate Potential for Submission of a Tivozanib MAA for the Treatment of RCC CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 8, 2015-- AVEO Oncology (NASDAQ:AVEO) today announced that it has received written confirmation from the European Medicine Agency (EMA) that tivozanib is eligible for submission of an application for a European Union Marketing Authorization under the Agency’s centralized procedure. Confirmation of eligibility was giv... 
Printer Friendly Version
More Press Releases >>
Upcoming Events 
There are currently no events scheduled.
More Events >>
Presentations 
Date
01/23/15
Efficacy and safety data from patients with advanced renal cell cancer treated with tivozanib hydrochloride after progression on sorafenib
09/29/14
Phase 2 clinical evaluation of preclinically defined biomarkers for vascular endothelial growth factor tyrosine kinase inhibitor tivozanib in renal cell carcinoma
09/29/14
BATON-CRC: a phase 2 randomized trial comparing tivozanib + mFOLFOX6 with bevacizumab + mFOLFOX6 in stage IV metastatic colorectal cancer
09/29/14
Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic-based subgroups of patients with previously untreated lung adenocarcinoma
05/31/14
First in human Phase 1 dose-escalation study of AV-203; #395, J. Sarantopoulos
More Presentations >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.